This study enrolled 102 patients from different ethnic minorities who were diagnosed with hepatitis C (with positive serum anti-HCV) at the Second Hospital of Dalian Medical University, Anshan Central Hospital, and the Second People's Hospital of Fuxin City between November 2011 and November 2019. Investigators obtained informed consent before enrolling participants into this study. All patients met the diagnostic criteria of the Guidelines for the Prevention and Treatment of Hepatitis C, which was formulated by the Chinese Society of Hepatology and Society of Infectious Diseases.[7] The study was approved by the Research Ethics Committee of Dalian Medical University, Liaoning, China. All patients provided written informed consent.